You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Pirlindole mesylate
Pirlindole mesylate is a highly selective reversible inhibitor of monoamine oxidase type A.
Technical Data for Pirlindole mesylate
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Pirlindole mesylate
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||16.12||50 with gentle warming|
Preparing Stock Solutions for Pirlindole mesylate
The following data is based on the product molecular weight 322.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||6.2 mL||31.02 mL||62.03 mL|
|2.5 mM||1.24 mL||6.2 mL||12.41 mL|
|5 mM||0.62 mL||3.1 mL||6.2 mL|
|25 mM||0.12 mL||0.62 mL||1.24 mL|
Product Datasheets for Pirlindole mesylate
References for Pirlindole mesylate
References are publications that support the biological activity of the product.
Mashkovsky and Andreeva (1981) Pharmacological properties of 2,3,3α,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride (pirlindole), a new antidepressant. Arzneim.-Forsch.Drug Res. 31 75 PMID: 7194096
Medvedev et al (1992) Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A in the prevention of experimentally induced epiletic seizures. Drug Investigation. 4 501
If you know of a relevant reference for Pirlindole mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Pirlindole mesylate, Pirlindole mesylate supplier, MAO-A, inhibitors, inhibits, MAO, Monoamine, Oxygenases, Oxidases, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 0724, Tocris Bioscience
1 Citation for Pirlindole mesylate
Citations are publications that use Tocris products. Selected citations for Pirlindole mesylate include:
Njagi et al (2010) Electrochemical quantification of serotonin in the live embryonic zebrafish intestine. Anal Chem 82 1822 PMID: 20148518
Do you know of a great paper that uses Pirlindole mesylate from Tocris? Please let us know.
Reviews for Pirlindole mesylate
There are currently no reviews for this product. Be the first to review Pirlindole mesylate and earn rewards!
Have you used Pirlindole mesylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.